Ayşegül İyidoğan

Dr. Ayşegül İyidoğan

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

26 May 2016 in Chirality
Verified
Journal Article
Closed access
PDF file
Eyüp BaşaranEyüp Başaran
Eyüp Başaran
AİAyşegül İyidoğan
Ayşegül İyidoğan
DSDomique Schols
Domique Schols
EOEmine Elçin Oruç‐Emre
Emine Elçin Oruç‐Emre

18 July 2024 in Bioorganic Chemistry
Verified
Journal Article
Closed access
AİAyşegül İyidoğan
Ayşegül İyidoğan
Eyüp BaşaranEyüp Başaran
Eyüp Başaran
GTGizem Tatar-Yılmaz
Gizem Tatar-Yılmaz
EOEmine Elçin Oruç-Emre
Emine Elçin Oruç-Emre

5 May 2023 in Journal of Molecular Recognition
Verified
Journal Article
Closed access
YSYusuf Sıcak
Yusuf Sıcak
HKHüseyin Kekeçmuhammed
Hüseyin Kekeçmuhammed
AİAyşegül İyidoğan
Ayşegül İyidoğan
Tugba Taskin-TokTugba Taskin-Tok
Tugba Taskin-Tok
EOEmine Elçin Oruç‐Emre
Emine Elçin Oruç‐Emre
MOMehmet OZTURK
Mehmet OZTURK

11 April 2019 in Chirality
Verified
Journal Article
Closed access
PDF file
Eyüp BaşaranEyüp Başaran
Eyüp Başaran
YSYusuf Sıcak
Yusuf Sıcak
HSHatice Gamze Sogukomerogullari
Hatice Gamze Sogukomerogullari
AİAyşegül İyidoğan
Ayşegül İyidoğan
EOEmine Elçin Oruç‐Emre
Emine Elçin Oruç‐Emre
MOMehmet OZTURK
Mehmet OZTURK

26 February 2025 in ACS Omega
Verified
Journal Article
Open access
BABedriye Seda Kurşun Aktar
Bedriye Seda Kurşun Aktar
YSYusuf Sıcak
Yusuf Sıcak
ABAbdulkadir Bakırdöven
Abdulkadir Bakırdöven
GYGizem Tatar Yılmaz
Gizem Tatar Yılmaz
ÖYÖzlem Yılmaz
Özlem Yılmaz
EOEmine Elçin Oruç-Emre
Emine Elçin Oruç-Emre
A series of chalcones containing a pyrrolidine moiety were synthesized to examine their in vitro α-amylase and α-glucosidase inhibitory activities, for the treatment of Diabetes mellitus, which is one of the most dangerous and rapidly increasing disorders of today. Compound 3 exhibited an excellent dual inhibitory effect with an IC50 value of 14.61 ± 0.12 μM against α-amylase, and with an IC50: 25.38 ± 2.09 μM against α-glucosidase. The in vitro cytotoxic effects of all compounds against nonsmall lung cancer (A549) and bronchial epithelial normal (BEAS-2B) cell lines were also evaluated. Compound 5 (IC50: 82.20 μM) and compound 8 (IC50: 59.96 μM) showed better cytotoxic activity than cisplatin against A549 (IC50: 84.39 μM) cells. Furthermore, these compounds had no harmful effect on healthy BEAS-2B cells at the determined IC50 values. Moreover, the molecular docking and molecular dynamics simulation analysis revealed that all synthesized compounds exhibited stronger binding affinities toward α-glucosidase and α-amylase compared to the positive control acarbose.